BioCentury
ARTICLE | Clinical News

Vimizim elosulfase alfa regulatory update

July 28, 2014 7:00 AM UTC

BioMarin said Health Canada approved an NDS for Vimizim elosulfase alfa as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA (MPS IVA, Morquio’...